Skip to main content
SUTRO BIOPHARMA, INC. logo

SUTRO BIOPHARMA, INC. — Investor Relations & Filings

Ticker · STRO ISIN · US8693671021 LEI · 5493005U6P15VD25P851 US Manufacturing
Open in API
Filings indexed 586 across all filing types
Latest filing 2018-08-29 Capital/Financing Update
Country US United States of America
Listing US STRO

About SUTRO BIOPHARMA, INC.

https://www.sutrobio.com/

Sutro Biopharma, Inc. is a clinical-stage biotechnology company focused on the discovery, development, and manufacturing of precisely designed cancer therapeutics. The company leverages its proprietary, integrated cell-free protein synthesis platform to create novel antibody-drug conjugates (ADCs). This technology enables the development of next-generation ADCs, including those with single and dual payloads, which are designed to offer improved therapeutic profiles for patients with cancer. Sutro is advancing its own pipeline of clinical-stage product candidates to address areas of significant unmet medical need.

Recent filings

Filing Released Lang Actions
S-1
Capital/Financing Update Classification · 100% confidence The document is a Form S-1 Registration Statement filed with the U.S. Securities and Exchange Commission (SEC) for Sutro Biopharma, Inc. It is a registration statement under the Securities Act of 1933, used for initial public offerings (IPOs) or other securities offerings. The text includes details about the offering, company overview, risk factors, use of proceeds, management discussion, and financial data. This is not an annual report, earnings release, or any other type of financial report but a registration statement for a securities offering. According to the filing definitions, this corresponds to a Capital/Financing Update (CAP) as it relates to company fundraising and capital structure changes.
2018-08-29 English
Regulatory Filings 2018
Regulatory Filings
2018-08-24 English
Regulatory Filings 2018
Regulatory Filings Classification · 95% confidence The document is a letter from the company's legal counsel to the SEC staff regarding amendments to a draft Registration Statement on Form S-1. It discusses revisions to charts in the Registration Statement and additional disclosures about risk factors. The document is a correspondence related to a regulatory filing process, specifically an amendment to a draft registration statement for an IPO or securities offering. It does not contain financial statements, earnings data, or detailed report content. The document length is 3568 characters, which is relatively short and consistent with a regulatory correspondence or filing amendment letter. Therefore, it is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous regulatory communications that do not fit other specific categories.
2018-08-21 English
Regulatory Filings 2018
Regulatory Filings Classification · 100% confidence The document is a letter from the company's legal counsel responding to comments from the SEC staff regarding a Draft Registration Statement on Form S-1. It discusses amendments and clarifications to the registration statement, including pipeline disclosures and collaboration agreements. The document is a regulatory correspondence related to a registration filing, not a financial report, earnings release, or other types of filings. It does not contain financial statements or detailed financial data but is a response to SEC comments on a registration statement. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory correspondence and compliance documents that do not fit other specific categories.
2018-08-09 English
Regulatory Filings 2018
Regulatory Filings
2018-08-08 English
Regulatory Filings 2018
Regulatory Filings
2018-07-30 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.